

## CURRENT REPORT 05/2022

April 27<sup>th</sup>, 2022

### Ryvu Therapeutics to present recent RVU120 and SEL24 (MEN1703) data at ASCO 2022 Annual Meeting

The Management Board of Ryvu Therapeutics S.A. with its registered office in Kraków ("Company") informs that during the upcoming American Association of Clinical Oncology Research (ASCO) Annual Meeting 2022, June 3-7 2022, Company will present the latest data of its oncology projects: RVU120 (SEL120), a program developing a selective CDK8/19 kinase inhibitor as an effective therapy for the treatment of hematologic malignancies and solid tumors, as well as a selective PIM/FLT3 inhibitor SEL24 (MEN1703), currently under development by Menarini Group. The obtained results provide rationale for further development of the above projects.

Details of abstracts accepted for publication:

- **Title:** *Phase 1/2 study of SEL24/MEN1703, a first-in-class dual PIM/FLT3 kinase inhibitor, in patients with IDH1/2-mutated acute myeloid leukemia: The DIAMOND-01 trial*  
**Session Title:** Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant  
**Abstract number:** 7024  
**Session date and time:** Saturday, June 4, 2022, 8:00 AM-11:00 AM CDT
- **Title:** *Phase I/II trial of RVU120 (SEL120), a CDK8/CDK19 inhibitor in patients with relapsed/refractory metastatic or advanced solid tumors*  
**Abstract Number (online publication only):** e15091

The full texts of ASCO Abstracts will be released on May 26, 2022 at 5:00 PM (EDT) / 11:00 PM (CET).

Additional information is available on the ASCO conference website:

<https://conferences.asco.org/am/abstracts>.

The information was considered significant because the research results of projects in the Company's pipeline are of key importance for its valuation, and the ASCO conference is considered one of the most important scientific events, gathering researchers, as well as potential clients and business partners - biotechnology and pharmaceutical companies and industry investors.

**Legal basis:** Article 17.1 of MAR

**Representatives of the Issuer:**

- Paweł Przewięźlikowski – President of the Management Board
- Krzysztof Brzózka – Vice President of the Management Board